TD Cowen Maintains Buy on Exagen, Lowers Price Target to $10
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $13 to $10.
TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $13 to $10.